Status:
TERMINATED
On Open-Label Study in Participants With Systemic Lupus Erythematosus
Lead Sponsor:
Eli Lilly and Company
Conditions:
Systemic Lupus Erythematosus
Connective Tissue Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
Eligibility Criteria
Inclusion
- Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)
- Given written informed consent
- Test negative for pregnancy at the time of enrollment
- Agree to use a reliable method of birth control
Exclusion
- Unwilling to comply with study procedures
- Any condition that renders the participants unable to understand the nature and scope and possible consequences of the study
- Any condition that in the opinion of the investigator poses an unacceptable risk to the participants if study drug would be administered
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
1518 Patients enrolled
Trial Details
Trial ID
NCT01488708
Start Date
January 1 2012
End Date
October 1 2015
Last Update
May 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician
Irving, Texas, United States, 75061